Cargando…

Safety, tolerability, and pharmacokinetics of single‐ and multiple‐dose administration of islatravir (MK‐8591) in adults without HIV

Islatravir (MK‐8591) is a nucleoside analogue in development for the treatment and prevention of HIV‐1. Two phase 1 trials were conducted during initial evaluation of islatravir: rising single doses (Study 1) and rising multiple doses (Study 2) of oral islatravir in male and female participants with...

Descripción completa

Detalles Bibliográficos
Autores principales:	Matthews, Randolph P., Ankrom, Wendy, Friedman, Evan, Jackson Rudd, Deanne, Liu, Yang, Mogg, Robin, Panebianco, Deborah, De Lepeleire, Inge, Petkova, Magdalena, Grobler, Jay A., Stoch, Selwyn Aubrey, Iwamoto, Marian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8504818/ https://www.ncbi.nlm.nih.gov/pubmed/34463432 http://dx.doi.org/10.1111/cts.13048

Ejemplares similares

A Phase 1 Study to Evaluate the Drug Interaction Between Islatravir (MK-8591) and Doravirine in Adults Without HIV
por: Matthews, Randolph P., et al.
Publicado: (2021)

A phase 1, open‐label study to evaluate the drug interaction between islatravir (MK‐8591) and the oral contraceptive levonorgestrel/ethinyl estradiol in healthy adult females
por: Ankrom, Wendy, et al.
Publicado: (2021)

551. MK-8591 Does Not Alter the Pharmacokinetics of the Oral Contraceptives Ethinyl Estradiol and Levonorgestrel
por: Ankrom, Wendy, et al.
Publicado: (2018)

546. No Difference in MK-8591 and Doravirine Pharmacokinetics After Co-Administration
por: Matthews, Randolph, et al.
Publicado: (2018)

Pharmacokinetic and Safety Profile of the Novel HIV Nonnucleoside Reverse Transcriptase Inhibitor MK-8507 in Adults without HIV
por: Ankrom, Wendy, et al.
Publicado: (2021)

Safety and Pharmacokinetics of Islatravir in Individuals with Severe Renal Insufficiency
por: Matthews, Randolph P., et al.
Publicado: (2022)

Lack of a Clinically Meaningful Drug Interaction Between the HIV‐1 Antiretroviral Agents Islatravir, Dolutegravir, and Tenofovir Disoproxil Fumarate
por: Rudd, Deanne Jackson, et al.
Publicado: (2021)

Single Oral Doses of MK-8507, a Novel Non-Nucleoside Reverse Transcriptase Inhibitor, Suppress HIV-1 RNA for a Week
por: Schürmann, Dirk, et al.
Publicado: (2022)

Fluoride Pharmacokinetics in Urine and Plasma Following Multiple Doses of MK‐8507, an Investigational, Oral, Once‐Weekly Nonnucleoside Reverse Transcriptase Inhibitor
por: Gillespie, Gillian, et al.
Publicado: (2021)

A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Trial of Radiopaque Islatravir-Eluting Subdermal Implants for Pre-exposure Prophylaxis Against HIV-1 Infection
por: Matthews, Randolph P., et al.
Publicado: (2023)

A Phase 1 Trial to Evaluate the Relationship Between Fluoride Intake and Urinary Fluoride Excretion in Healthy Participants
por: Gillespie, Gillian, et al.
Publicado: (2021)

Assessment of Pharmacokinetic Interaction Between Gefapixant (MK‐7264), a P2X3 Receptor Antagonist, and the OATP1B1 Drug Transporter Substrate Pitavastatin
por: McCrea, Jacqueline B., et al.
Publicado: (2021)

Brief Report: Efficacy and Safety of Oral Islatravir Once Daily in Combination With Doravirine Through 96 Weeks for Treatment-Naive Adults With HIV-1 Infection Receiving Initial Treatment With Islatravir, Doravirine, and Lamivudine
por: Molina, Jean-Michel, et al.
Publicado: (2022)

Clinical Pharmacokinetics of the Novel HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitor Doravirine: An Assessment of the Effect of Patient Characteristics and Drug–Drug Interactions
por: Khalilieh, Sauzanne, et al.
Publicado: (2020)

Islatravir Is Not Expected to Be a Victim or Perpetrator of Drug-Drug Interactions via Major Drug-Metabolizing Enzymes or Transporters
por: Bleasby, Kelly, et al.
Publicado: (2021)

Evaluating Islatravir Administered Via Microneedle Array Patch for Long-Acting HIV Pre-exposure Prophylaxis Using Physiologically Based Pharmacokinetic Modelling
por: Kinvig, Hannah, et al.
Publicado: (2022)

Correction to: Evaluating Islatravir Administered Via Microneedle Array Patch for Long-Acting HIV Pre-exposure Prophylaxis Using Physiologically Based Pharmacokinetic Modelling
por: Kinvig, Hannah, et al.
Publicado: (2022)

Clinical Formulation Bridging of Gefapixant, a P2X3‐Receptor Antagonist, for the Treatment of Chronic Cough
por: Gupta, Pranav, et al.
Publicado: (2022)

HIV-1 Resistance to Islatravir/Tenofovir Combination Therapy in Wild-Type or NRTI-Resistant Strains of Diverse HIV-1 Subtypes
por: Cilento, Maria E., et al.
Publicado: (2023)

Characterization of the absorption, metabolism, excretion, and mass balance of gefapixant in humans
por: Nussbaum, Jesse C., et al.
Publicado: (2022)

Assessment of pharmacokinetics, safety, and tolerability following twice‐daily administration of molnupiravir for 10 days in healthy participants
por: Iwamoto, Marian, et al.
Publicado: (2023)

998. Forward and Reverse Translational Approaches to Predict Efficacy of the Neutralizing Respiratory Syncytial Virus (RSV) Antibody MK-1654
por: Maas, Brian M, et al.
Publicado: (2021)

Antidepressant Effects of (+)-MK-801 and (-)-MK-801 in the Social Defeat Stress Model
por: Yang, Bangkun, et al.
Publicado: (2016)

The acid–base and redox properties of menaquinone MK-4, MK-7, and MK-9 (vitamin K(2)) in DMPC monolayers on mercury
por: Dharmaraj, Karuppasamy, et al.
Publicado: (2020)

How young can children reliably and validly self-report their health-related quality of life?: An analysis of 8,591 children across age subgroups with the PedsQL™ 4.0 Generic Core Scales
por: Varni, James W, et al.
Publicado: (2007)

Ridaforolimus (MK-8669) synergizes with Dalotuzumab (MK-0646) in hormone-sensitive breast cancer
por: Becker, Marc A., et al.
Publicado: (2016)

Synchro Clock MkIV
por: Odier, P, et al.
Publicado: (2010)

Crucial Roles of the Protein Kinases MK2 and MK3 in a Mouse Model of Glomerulonephritis
por: Guess, Adam J., et al.
Publicado: (2013)

Cytotoxic activity of the MK2 inhibitor CMPD1 in glioblastoma cells is independent of MK2
por: Gurgis, FMS, et al.
Publicado: (2015)

Cooperative and distinct functions of MK2 and MK3 in the regulation of the macrophage transcriptional response to lipopolysaccharide
por: Ehlting, Christian, et al.
Publicado: (2019)

GROWTH CHARACTERISTICS OF MONKEY KIDNEY CELL STRAINS LLC-MK(1), LLC-MK(2), AND LLC-MK(2)(NCTC-3196) AND THEIR UTILITY IN VIRUS RESEARCH
por: Hull, R. N., et al.
Publicado: (1962)

A phase I, randomized, placebo‐controlled study of molnupiravir in healthy Japanese to support special approval in Japan to treat COVID‐19
por: Nakamura, Keisuke, et al.
Publicado: (2022)

Heat transfer at a sapphire – indium interface in the 30 mK – 300 mK temperature range
por: Liberadzka, J, et al.
Publicado: (2017)

Characterizing Class‐Specific Exposure‐Viral Load Suppression Response of HIV Antiretrovirals Using A Model‐Based Meta‐Analysis
por: Xu, Y, et al.
Publicado: (2016)

Aryl hydrocarbon receptor inhibits inflammation in DSS-induced colitis via the MK2/p-MK2/TTP pathway
por: Wang, Qimeng, et al.
Publicado: (2018)

MK-STYX Alters the Morphology of Primary Neurons, and Outgrowths in MK-STYX Overexpressing PC-12 Cells Develop a Neuronal Phenotype
por: Banks, Dallas A., et al.
Publicado: (2017)

Development, initial validation, and application of a visual read method for [(18)F]MK‐6240 tau PET
por: Shuping, Joanna L., et al.
Publicado: (2023)

mkESA: enhanced suffix array construction tool
por: Homann, Robert, et al.
Publicado: (2009)

Generalizing mkFit and its Application to HL-LHC
por: Tadel, Matevz
Publicado: (2023)

CaMK4 Gene Deletion Induces Hypertension
por: Santulli, Gaetano, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_2ikn7gcgqah64bju5c3f8l239k